|
|
Exploring the potential mechanisms of impairment on genitourinary system associated with coronavirus disease 2019 infection: Bioinformatics and molecular simulation analyses |
Kai Zhaoa,b,Dong Zhanga,b,Xinchi Xua,b,Shangqian Wanga,b,Zhanpeng Liua,b,Xiaohan Rena,b,Xu Zhanga,b,Zhongwen Lua,b,Shancheng Renc,*( ),Chao Qina,b,*( )
|
a Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China b The State Key Laboratory of Reproductive Medicine, Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China c Department of Urology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China |
|
|
Abstract Objective The novel coronavirus (severe acute respiratory syndrome coronavirus 2) has been spreading worldwide since December 2019, posing a serious danger to human health and socioeconomic development. A large number of clinical trials have revealed that coronavirus disease 2019 (COVID-19) results in multi-organ damage including the urogenital system. This study aimed to explore the potential mechanisms of genitourinary damage associated with COVID-19 infection through bioinformatics and molecular simulation analysis. Methods We used multiple publicly available databases to explore the expression patterns of angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), and CD147 in major organs in the healthy and disease-specific populations, particularly the genitourinary organs. Single-cell RNA sequencing was used to analyze the cell-specific expression patterns of ACE2, TMPRSS2, CD147, cytokine receptors, and cytokine interacting proteins in genitourinary organs, such as the bladder, kidney, prostate, and testis. Additionally, gene set enrichment analysis was used to investigate the relationship between testosterone levels and COVID-19 vulnerability in patients with prostate cancer. Results The results revealed that ACE2, TMPRSS2, and CD147 were highly expressed in normal urogenital organs. Then, they were also highly expressed in multiple tumors and chronic kidney diseases. Additionally, ACE2, TMPRSS2, and CD147 were significantly expressed in a range of cells in urogenital organs according to single-cell RNA sequencing. Cytokine receptors and cytokine interacting proteins, especially CCL2, JUN, and TIMP1, were commonly highly expressed in urogenital organs. Finally, gene set enrichment analysis results showed that high testosterone levels in prostate cancer patients were significantly related to the JAK-STAT signaling pathway and the Toll-like receptor signaling pathway which were associated with COVID-19. Conclusion Our study provides new insights into the potential mechanisms of severe acute respiratory syndrome coronavirus 2 damage to urogenital organs from multiple perspectives, which may draw the attention of urologists to COVID-19 and contribute to the development of targeted drugs.
|
Received: 27 August 2022
Available online:
|
Corresponding Authors:
Shancheng Ren,Chao Qin
E-mail: renshancheng@gmail.com;nmuqinchao@163.com
|
|
|
|
The expression of ACE2, TMPRSS2, and CD147 in normal human tissue from multiple public databases. (A) The mRNA expression pattern of ACE2 in HPA, GTEx, and FANTOM5; (B) The protein expression pattern of ACE2 in HPA; (C) The mRNA expression pattern of TMPRSS2 in HPA, GTEx, and FANTOM5; (D) The protein expression pattern of TMPRSS2 in HPA; (E) The mRNA expression pattern of CD147 in GTEx; (F) The protein expression pattern of CD147 in HPA. ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane serine protease 2; HPA, Human Protein Atlas; GTEx, the genotype-tissue Expression; FANTOM5, the Functional Annotation Of The Mammalian Genome.
|
|
The ACE2 and CD147 protein concentration and distribution between male and female in plasma. (A and B) The concentration of ACE2 and CD147 in human plasma is quantified by mass spectrometry-based plasma proteomics and estimated from spectral counts in a publicly available data set obtained from the PeptideAtlas (ACE2: 400 ng/L, CD147: 340 ng/L); (C and D) Violin plot showing the distribution of ACE2 and CD147 between male and female in plasma, based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with three visits during 2 years; and protein expression levels are reported as NPX. ACE2, angiotensin-converting enzyme 2; NPX, normalized protein expression.
|
|
Expression patterns of ACE2, TMPRSS2, and CD147 mRNA in specific patient populations. (A) The mRNA expression patterns of ACE2 in 33 kinds of tumors in TCGA; (B) Differential mRNA expression of ACE2 in 33 kinds of tumor tissue and normal tissue from TCGA; (C) The mRNA expression patterns of TMPRSS2 in 33 kinds of tumors in TCGA; (D) Differential mRNA expression of TMPRSS2 in 33 kinds of tumor tissue and normal tissue from TCGA; (E) The mRNA expression patterns of CD147 in 33 kinds of tumors in TCGA; (F) Differential mRNA expression of CD147 in 33 kinds of tumor tissue and normal tissue from TCGA; (G) The mRNA expression patterns of ACE2 in GSE66494; (H) The mRNA expression patterns of TMPRSS2 in GSE66494; (I) The mRNA expression patterns of CD147 in GSE66494. ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane serine protease 2; CKD, chronic kidney disease; ns, no significant. ?p<0.05, ??p<0.01, ???p<0.001, ????p<0.0001.
|
|
Cell-specific mRNA expressions of ACE2, TMPRSS2, and CD147 in bladder, kidney, prostate, and testis. (A) Cell-specific expression of ACE2 from Human Cell Landscape Kidney2 (http://bis.zju.edu.cn/HCL/search.html); (B) Cell-specific expression of ACE2 from Human Cell Landscape Testis_Guo (http://bis.zju.edu.cn/HCL/search.html); (C) Cell-specific expression of TMPRSS2 from Human Cell Landscape Kidney2 (http://bis.zju.edu.cn/HCL/search.html); (D) Cell-specific expression of TMPRSS2 from Human Cell Landscape Prostate1 (http://bis.zju.edu.cn/HCL/search.html); (E) Cell-specific expression of TMPRSS2 from Human Cell Landscape Testis_Guo (http://bis.zju.edu.cn/HCL/search.html); (F) Cell-specific expression of CD147 from Human Cell Landscape Bladder1 (http://bis.zju.edu.cn/HCL/search.html); (G) Cell-specific expression of CD147 from Human Cell Landscape Kidney2 (http://bis.zju.edu.cn/HCL/search.html); (H) Cell-specific expression of CD147 from Human Cell Landscape Prostate1 (http://bis.zju.edu.cn/HCL/search.html); (I) Cell-specific expression of CD147 from Human Cell Landscape Testis_Guo (http://bis.zju.edu.cn/HCL/search.html). ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane serine protease 2; HPA, Human Protein Atlas; GTEx, the Genotype-Tissue Expression; FANTOM5, the Functional Annotation of The Mammalian Genome.
|
|
Cell-specific expression of cytokine receptors and cytokine interacting proteins in bladder, kidney, prostate, and testis. (A) Cell-specific expression of cytokine receptors and cytokine interacting proteins from Human Cell Landscape Bladder1 (http://bis.zju.edu.cn/HCL/search.html); (B) Cell-specific expression of cytokine receptors and cytokine interacting proteins from Human Cell Landscape Kidney2 (http://bis.zju.edu.cn/HCL/search.html); (C) Cell-specific expression of cytokine receptors and cytokine interacting proteins from Human Cell Landscape Prostate1 (http://bis.zju.edu.cn/HCL/search.html); (D) Cell-specific expression of cytokine receptors and cytokine interacting proteins from Human Cell Landscape Testis_Guo (http://bis.zju.edu.cn/HCL/search.html).
|
|
GSEA enrichment plots of GSE72920 dataset. (A) GSEA enrichment plot: JAK-STAT signaling pathway; (B) GSEA enrichment plot: Toll-like receptor signaling pathway. GSEA, Gene Set Enrichment Analysis; JAK-STAT, Janus kinase-signal transducers and activators of transcription.
|
[1] |
Lu H, Stratton CW, Tang Y. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020; 92:401-2.
doi: 10.1002/jmv.25678
pmid: 31950516
|
[2] |
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270-3.
doi: 10.1038/s41586-020-2012-7
|
[3] |
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71-6.
|
[4] |
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26:1017-32.
doi: 10.1038/s41591-020-0968-3
pmid: 32651579
|
[5] |
Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, et al. Multi--organ proteomic landscape of COVID-19 autopsies. Cell 2021; 184:775-791.e14. https://doi.org/10.1016/j.cell.2021.01.004.
doi: 10.1016/j.cell.2021.01.004
|
[6] |
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-280. e8. https://doi.org/10.1016/j.cell.2020.02.052.
|
[7] |
Ren X, Wang S, Chen X, Wei X, Li G, Ren S, et al. Multiple expression assessments of ACE2 and TMPRSS2 SARS-CoV-2 entry molecules in the urinary tract and their associations with clinical manifestations of COVID-19. Infect Drug Resist 2020;13:3977-90.
|
[8] |
Fenizia C, Galbiati S, Vanetti C, Vago R, Clerici M, Tacchetti C, et al. SARS-CoV-2 entry: at the crossroads of CD147 and ACE2. Cells 2021;10:1434. https://doi.org/10.3390/cells10061434.
|
[9] |
Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020;75:2829-45.
|
[10] |
Su H, Wan C, Wang Z, Gao Y, Li Y, Tang F, et al. Expression of CD147 and cyclophilin A in kidneys of patients with COVID-19. Clin J Am Soc Nephrol 2021;16:618-9.
|
[11] |
Wang K, Chen W, Zhang Z, Deng Y, Lian J, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Targeted Ther 2020;5:283. https://doi.org/10.1038/s41392-020-00426-x.
|
[12] |
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033-4.
doi: S0140-6736(20)30628-0
pmid: 32192578
|
[13] |
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol 2021; 93:250-6.
doi: 10.1002/jmv.v93.1
|
[14] |
Samuel RM, Majd H, Richter MN, Ghazizadeh Z, Zekavat SM, Navickas A, et al. Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. Cell Stem Cell 2020;27:876-889. e12. https://doi.org/10.1016/j.stem.2020.11.009.
|
[15] |
Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59:4180-4.
pmid: 10485450
|
[16] |
Porcacchia AS, Andersen ML, Tufik S. Prostate cancer and SARS-CoV-2: possible intersections through the TMPRSS2 pathway. Eur J Cancer Prev 2021;30:481-3.
|
[17] |
Ebner B, Volz Y, Mumm J-N, Stief CG, Magistro G.The COVID-19 pandemicdwhat have urologists learned? Nat Rev Urol 2022; 19:344-56.
doi: 10.1038/s41585-022-00586-1
|
[18] |
Uhlén M, Fagerberg L, Hallstr?m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science 2015;347:1260419. https://doi.org/10.1126/science.1260419.
|
[19] |
Kawaji H, Kasukawa T, Forrest A, Carninci P, Hayashizaki Y. The FANTOM 5 collection, a data series underpinning mammalian transcriptome atlases in diverse cell types. Sci Data 2017; 4:170113. https://doi.org/10.1038/sdata.2017.113.
doi: 10.1038/sdata.2017.113
|
[20] |
Carithers LJ, Moore HM. The genotype-tissue expression GTEx project. Biopreserv Biobanking 2015; 13:307-8.
doi: 10.1089/bio.2015.29031.hmm
|
[21] |
Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, et al. Molecular markers of tubulointerstitial fibrosis and tubular cell damage in patients with chronic kidney disease. PLoS One 2015; 10:e0136994. https://doi.org/10.1371/journal.pone.0136994.
doi: 10.1371/journal.pone.0136994
|
[22] |
Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol 2016; 70:214-8.
doi: 10.1016/j.eururo.2015.10.042
pmid: 26572708
|
[23] |
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47:D607-13. https://doi.org/10.1093/nar/gky1131.
doi: 10.1093/nar/gky1131
|
[24] |
Han X, Zhou Z, Fei L, Sun H, Wang R, Chen Y, et al. Construction of a human cell landscape at single-cell level. Nature 2020; 581:303-9.
doi: 10.1038/s41586-020-2157-4
|
[25] |
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50.
doi: 10.1073/pnas.0506580102
|
[26] |
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267-73.
doi: 10.1038/ng1180
pmid: 12808457
|
[27] |
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Targeted Ther 2021; 6:255. https://doi.org/10.1038/s41392-021-00679-0.
doi: 10.1038/s41392-021-00679-0
|
[28] |
Khanmohammadi S, Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J Med Virol 2021; 93:2735-9. https://doi.org/10.1002/jmv.26826.
doi: 10.1002/jmv.26826
pmid: 33506952
|
[29] |
Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat Inflamm 2021;2021:8874339. https://doi.org/10.1155/2021/8874339.
|
[30] |
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Targeted Ther 2020;5:84. https://doi.org/10.1038/s41392-020-0191-1.
|
[31] |
Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what we think we know so far and what we don’t. J Nephrol 2020; 33:1213-8.
doi: 10.1007/s40620-020-00789-y
|
[32] |
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97:829-38.
doi: S0085-2538(20)30255-6
pmid: 32247631
|
[33] |
Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 2020;51:343-8.
|
[34] |
Chen L, Huang X, Yi Z, Deng Q, Jiang N, Feng C, et al. Ultrasound imaging findings of acute testicular infection in patients with coronavirus disease 2019: a single-center-based study in wuhan, China. J Ultrasound Med 2021; 40:1787-94.
doi: 10.1002/jum.15558
pmid: 33174632
|
[35] |
Liu Y, Song L, Zheng N, Shi J, Wu H, Yang X, et al. A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options. Sci China Life Sci 2022; 65:1866-80.
doi: 10.1007/s11427-021-2070-y
pmid: 35290573
|
[36] |
Gonzalez DC, Khodamoradi K, Pai R, Guarch K, Connelly ZM, Ibrahim E, et al. A systematic review on the investigation of SARS-CoV-2 in semen. Res Rep Urol 2020; 12:615-21.
doi: 10.2147/RRU.S277679
pmid: 33294423
|
[37] |
Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, et al. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril 2020;113:1135-9.
|
[38] |
Zhang S, Wang X, Zhang H, Xu A, Fei G, Jiang X, et al. The absence of coronavirus in expressed prostatic secretion in COVID-19 patients in Wuhan city. Reprod Toxicol 2020; 96:90-4.
doi: S0890-6238(20)30165-9
pmid: 32534021
|
[39] |
Ruan Y, Hu B, Liu Z, Liu K, Jiang H, Li H, et al. No detection of SARS-CoV-2 from urine, expressed prostatic secretions, and semen in 74 recovered COVID-19 male patients: a perspective and urogenital evaluation. Andrology 2021;9:99-106.
|
[40] |
Nassau DE, Best JC, Kresch E, Gonzalez DC, Khodamoradi K, Ramasamy R. Impact of the SARS-CoV-2 virus on male reproductive health. BJU Int 2022; 129:143-50.
doi: 10.1111/bju.v129.2
|
[41] |
Mumm JN, Osterman A, Ruzicka M, Stihl C, Vilsmaier T, Munker D, et al. Urinary frequency as a possibly overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis? Eur Urol 2020;78:624-8.
|
[42] |
Dhar N, Dhar S, Timar R, Lucas S, Lamb LE, Chancellor MB. De novo urinary symptoms associated with COVID-19: COVID-19-associated cystitis. J Clin Med Res 2020;12:681-2.
|
[43] |
Su H, Yang M, Wan C, Yi L, Tang F, Zhu H, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020;98:219-27.
|
[44] |
Santoriello D, Khairallah P, Bomback AS, Xu K, Kudose S, Batal I, et al. Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol 2020; 31:2158-67.
doi: 10.1681/ASN.2020050744
pmid: 32727719
|
[45] |
Illiano E, Trama F, Costantini E.Could COVID-19 have an impact on male fertility? Andrologia 2020; 52:e13654. https://doi.org/10.1111/and.13654.
|
[46] |
Carlsen E, Andersson AM, Petersen JH, Skakkebaek NE. History of febrile illness and variation in semen quality. Hum Reprod 2003; 18:2089-92.
pmid: 14507826
|
[47] |
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Targeted Ther 2020;5:84. https://doi.org/10.1038/s41392-020-0191-1.
|
[48] |
Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Arch Chest Dis 2020: 90. https://doi.org/10.4081/monaldi.2020.1389.
|
[49] |
Mukherjee S, Pahan K.Is COVID-19 gender-sensitive? J Neuroimmune Pharmacol 2021; 16:38-47.
doi: 10.1007/s11481-020-09974-z
|
[50] |
Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metabol 2020; 22:1915-24.
doi: 10.1111/dom.v22.10
|
[51] |
Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. PLoS One 2021; 16:e0250602. https://doi.org/10.1371/journal.pone.0250602.
doi: 10.1371/journal.pone.0250602
|
[52] |
Leow MKS. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19. Crit Care 2020;24:396. https://doi.org/10.1186/s13054-020-03097-w.
|
[53] |
Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a populationbased study (nZ4532). Ann Oncol 2020;31:1040-5.
|
[54] |
Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol 2020;30:484-7.
|
[1] |
Ponco Birowo,Nur Rasyid,Chaidir A. Mochtar,Bambang S. Noegroho,H.R. Danarto,Besut Daryanto,Lukman Hakim,Dyandra Parikesit,Fakhri Rahman,S. Cahyo Ariwicaksono. Daily activities and training experiences of urology residents during the coronavirus disease 2019 pandemic in Indonesia: A nationwide survey[J]. Asian Journal of Urology, 2023, 10(2): 119-127. |
[2] |
Gede Wirya Kusuma Duarsa,Yudit Anastasia Sari,Anak Agung Gde Oka,Kadek Budi Santosa,I Wayan Yudiana,Pande Made Wisnu Tirtayasa,Ida Bagus Putra Pramana,Yudhistira Pradnyan Kloping. Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients[J]. Asian Journal of Urology, 2021, 8(3): 289-297. |
[3] |
Kuangzheng Liu,Xinglin Chen,Xiaohan Ren,Yuqing Wu,Shancheng Ren,Chao Qin. SARS-CoV-2 effects in the genitourinary system and prospects of sex hormone therapy[J]. Asian Journal of Urology, 2021, 8(3): 303-314. |
[4] |
Youssef Kharbach,Abdelhak Khallouk. Male genital damage in COVID-19 patients: Are available data relevant?[J]. Asian Journal of Urology, 2021, 8(3): 324-326. |
[5] |
Abhishek Tripathi,Shilpa Gupta. Androgen receptor in bladder cancer: A promising therapeutic target[J]. Asian Journal of Urology, 2020, 7(3): 284-290. |
[6] |
Michael V. Fiandalo,Daniel T. Gewirth,James L. Mohler. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 50-56. |
[7] |
Graziele Halmenschlager, Ernani Luis Rhoden, Gabriela Almeida Motta, Lucas Sagrillo Fagundes, Jorge Luiz Medeiros Jr, Rosalva Meurer, Cláudia Ramos Rhoden. Testosterone replacement maintains smooth muscle content in the corpus cavernosum of orchiectomized rats[J]. Asian Journal of Urology, 2017, 4(4): 223-229. |
[8] |
Nikhil Gupta, Maria Carvajal, Michael Jurewicz, Bruce R. Gilbert. Bulbocavernosus muscle area as a novel marker for hypogonadism[J]. Asian Journal of Urology, 2017, 4(1): 3-9. |
[9] |
Antonio B. Porcaro, Aldo Petrozziello, Matteo Brunelli, Filippo Migliorini, Giovanni Cacciamani, Davide De Marchi, Nicolo' de Luyk, Irene Tamanini, Beatrice Caruso, Maria A. Cerruto, Claudio Ghimenton, Walter Artibani. Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume)[J]. Asian Journal of Urology, 2016, 3(1): 26-32. |
|
|
|
|